Pathology and Surgical Treatment of Craniopharyngiomas
Craniopharyngiomas are rare epithelial tumours that develop in the sellar and suprasellar region, close to the pituitary stalk, optic chiasm and hypothalamus. Although most are histologically benign, their anatomical position allows even a small mass to obstruct cerebrospinal fluid flow, impair vision or disrupt hormonal control. The central surgical challenge is therefore not simply removal, but preserving vital neurological function while achieving durable tumour control.
Pathology helps explain their varied behaviour. Adamantinomatous tumours contain epithelial remnants resembling the enamel organ of developing teeth, while papillary tumours resemble squamous epithelium and usually lack calcification. The distinction matters in children, where adamantinomatous disease is dominant, and in adults, where papillary lesions are more common. It also informs imaging interpretation, molecular testing and the need for adjuvant therapy after incomplete resection.
Modern care is multidisciplinary. Neurosurgeons work with neuro-ophthalmologists, endocrinologists, neuroradiologists, neurophysiologists, neuropsychologists and radiation oncologists. For patients and families in Australia, this coordination is particularly important because treatment may continue for years beyond the operation, with consequences involving growth, hormones, cognition, weight, vision and school or work participation.
Developmental origins and pathological patterns
Most craniopharyngiomas are believed to arise from embryonic remnants of Rathke’s pouch, the epithelial structure that gives rise to the anterior pituitary. These remnants may persist near the infundibulum and develop into a cystic, solid or mixed lesion. Although classified as WHO grade 1 tumours, their location can produce serious neurological and endocrine effects. Small lesions near the chiasm may cause predominantly visual symptoms, while large third-ventricular extensions can obstruct cerebrospinal fluid circulation and create acute hydrocephalus.
The adamantinomatous variant is the characteristic form in childhood. Histology typically shows palisading squamous epithelium, loose stellate reticulum, nodules of “wet keratin” and dystrophic calcification. CT may demonstrate calcification more clearly than MRI, while MRI defines the relationship between the tumour, optic pathways, stalk and hypothalamus. Activating changes in CTNNB1, which produces nuclear accumulation of beta-catenin, are characteristic molecular findings.
Papillary craniopharyngiomas occur mainly in adults and contain mature squamous epithelium supported by fibrovascular connective tissue. They are generally solid, less often calcified and frequently harbour a BRAF V600E mutation. These differences influence both recurrence risk and the potential role of targeted treatment. A pathology review is essential when an unusual adult lesion might have a papillary component. For broader discussion of how diagnostic observations translate into clinical decisions, readers can also explore near the lighthouse.
Clinical effects and diagnostic warning signs
The presenting symptoms depend on tumour size, growth pattern and proximity to the optic chiasm and hypothalamic structures. Compression of the chiasm may produce bitemporal hemianopia, in which the outer visual fields of both eyes are lost, although asymmetrical field defects are also common. Headache, vomiting, papilloedema and hydrocephalus can indicate raised intracranial pressure. A tumour may remain silent until it is advanced, particularly when visual decline is gradual and patients adapt by compensating with one eye.
Endocrine and metabolic abnormalities often accompany the neurological features. Growth hormone deficiency can cause short stature and reduced school performance; central hypothyroidism, ACTH deficiency and gonadotropin deficiency may develop together. Central diabetes insipidus produces intense thirst, polyuria and hypernatraemia. Hypothalamic involvement may disturb appetite regulation, sleep, body temperature, thirst and behaviour, sometimes causing rapid weight gain that is resistant to conventional advice.
The clinical course can be less obvious than the anatomy suggests. A child may present with poor growth and declining school marks rather than a named neurological deficit, while an adult may describe fatigue, visual problems or menstrual disturbance. In Australia, sudden visual loss, confusion, repeated vomiting, severe dehydration or collapse warrants urgent assessment through the ambulance service or an emergency department rather than waiting for a routine specialist appointment.
Preoperative assessment and team planning
MRI with contrast is the principal imaging test for defining the tumour’s origin, suprasellar extension, relationship to the third ventricle and involvement of the pituitary stalk. CT complements MRI when calcification or bone detail is important. Careful review in the sagittal and coronal planes helps determine whether a lesion is prechiasmatic, retrochiasmatic or predominantly posterior, because that relationship strongly influences the safest surgical route.
Formal visual-field testing and neuro-ophthalmic review establish a baseline and identify compression of the chiasm or optic nerves. Endocrine evaluation includes morning cortisol and ACTH, thyroid function, prolactin, gonadal hormones, electrolytes, serum osmolality and measures of growth and puberty. Blood tests may need careful interpretation because illness, stress and previous treatment can alter results. Neurocognitive testing is particularly valuable for children and for adults with subtle memory or executive-function difficulties.
The operation should be planned by a team capable of managing more than the tumour itself. Perioperative steroid cover may be required when ACTH deficiency is present, and diabetes insipidus or sodium disturbances need close surveillance after surgery. In the Australian health system, elective treatment commonly follows a referral pathway involving a general practitioner, treating specialist and neurosurgical centre, with Medicare supporting many public and private services. Access, urgency and out-of-pocket costs can vary, so patients should receive clear information about expected hospital arrangements and ongoing medication.
Selecting the safest surgical route
The objective is maximal safe resection while preserving the optic apparatus, hypothalamic nuclei, pituitary stalk and normal vascular structures. This does not always mean removing every visible fragment. A small residual tumour adjacent to the hypothalamus may carry a lower long-term cost than complete resection that causes irreversible injury. Conversely, a well-separated lesion with limited hypothalamic contact may be suitable for aggressive resection with a high chance of durable control.
An endoscopic endonasal approach provides direct access to midline sellar and suprasellar lesions without brain retraction. It is particularly useful for lesions extending into the third ventricle through the floor, provided that the vascular anatomy is suitable. Its specific risks include cerebrospinal fluid leakage and postoperative nasal complications. Transcranial approaches, including pterional and interhemispheric routes, may offer better access to marked lateral extension, large third-ventricular components or vessels that cannot safely be approached through the nose. Some complex tumours require a staged or combined strategy.
Intraoperative navigation, Doppler imaging, careful haemostasis and monitoring of visual and endocrine functions support safer dissection. Surgeons also assess whether the tumour is merely adjacent to the hypothalamus or infiltrates it, since this distinction predicts postoperative obesity, memory difficulties and other complications. For difficult anatomical and ethical decisions, the clinical discussion forum provides a place for clinicians and students to compare reasoning without replacing the judgement of the treating multidisciplinary team.
Extent of resection and adjuvant treatment
The choice between gross-total and subtotal resection depends on tumour boundaries and the condition of adjacent neural structures. Complete removal can reduce recurrence and may spare later radiotherapy, but it may also produce permanent pituitary, hypothalamic or cognitive deficits. If substantial residual tumour remains, image-guided fractionated radiotherapy or stereotactic radiosurgery may provide control. Decisions are individualised according to age, residual volume, prior treatment, proximity to critical structures and the consequences of radiation.
In children, radiation is often deferred when it can be avoided because of its effects on the developing brain. Selected cystic tumours may be treated by repeated drainage and intracystic agents such as interferon-alpha under a specialist protocol. For papillary tumours carrying BRAF V600E, targeted BRAF and MEK inhibition has become a relevant option for selected recurrent or unresectable disease, although surgery remains the usual starting point when circumstances permit.
The principal pathological patterns differ in ways that affect presentation, imaging and treatment:
| Feature | Adamantinomatous craniopharyngioma | Papillary craniopharyngioma |
|---|---|---|
| Typical age group | Children and adolescents | Usually adults |
| Key histology | Palisading epithelium, stellate reticulum, wet keratin and frequent calcification | Mature squamous epithelium around fibrovascular cores, usually without calcification |
| Molecular hallmark | CTNNB1 activation and nuclear beta-catenin accumulation | BRAF V600E alteration |
| Imaging tendency | Often cystic or mixed solid-cystic and strongly calcified | More often solid, well defined and less calcified |
| Treatment implication | Intracystic treatment or radiotherapy may be needed for residual disease | Complete resection can be highly effective; targeted therapy has a role in selected recurrent cases |
Long-term follow-up is lifelong and should include MRI surveillance, endocrine replacement, visual assessment, growth and pubertal monitoring, metabolic review and evaluation of cognition, mood, sleep and weight. Recurrence can occur many years after treatment, while endocrine deficits and hypothalamic dysfunction may persist even when imaging shows no tumour. A coordinated plan helps prevent the burden of follow-up being concentrated on one specialist or a single metropolitan hospital.
Craniopharyngioma care across Australia
Specialist neurosurgical care is concentrated in tertiary centres in Melbourne, Sydney, Brisbane, Perth and Adelaide. Children are often treated through children’s hospitals with paediatric neurosurgery, endocrinology and ophthalmology available on the same campus, while adults may attend an adult centre with a separate pituitary multidisciplinary team. Families in regional and remote areas may need to travel to a metropolitan service for surgery and specialist review. Telehealth can support follow-up, but endocrine blood tests, formal visual-field testing and imaging still require appropriate local arrangements.
Access to long-term medicines also varies. Hydrocortisone, desmopressin, levothyroxine and other endocrine treatments are often subsidised through the Pharmaceutical Benefits Scheme, yet prescriptions, refrigeration needs and access to an experienced pharmacist can still matter. Aboriginal and Torres Strait Islander patients may benefit from coordinated care involving local Aboriginal Medical Services, community-controlled health services and regional clinicians. Culturally safe communication and practical transport support should be included in follow-up planning rather than treated as separate from the medical pathway.
For clinicians and students ready to deepen their understanding, the curated medical e-library provides a focused route into neurosurgical and medical literature. Register on Thamburaj, contribute a case-based reflection, reply to a colleague or subscribe for updates so that practical experience and responsible discussion continue to inform craniopharyngioma care.